# Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer

> **NCT02664103** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 2 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Fixed-dose combination of capecitabine and cyclophosphamide SAR439281

## Key facts

- **NCT ID:** NCT02664103
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-23
- **Primary completion:** 2017-11-06
- **Final completion:** 2017-11-06
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2018-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02664103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02664103, "Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02664103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*